Amgen Announces Top-Line Results From Otezla Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis; Study Showed Statistically Significant Improvement In Primary Endpoint, Met All Secondary Endpoints

by | Dec 1, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.